Aerska raised $21m recently for its RNA therapies tackling diseases like Alzheimer's. Co-founders Jack O’Meara and David Hardwicke talk to The Currency about what’s next.
At one time, Exyte, which works on data centres and pharma plants, was raking in more than €1bn in Ireland. As long-term projects conclude, the company is on the hunt for new business.
The start-up, often described as an "Uber for pathology", has just secured a crucial approval to carry out pathological testing in the UK. CEO Donal O'Shea speaks about building out its UK footprint and plans to scale up in the US.
The organisation has joined calls for a boycott of Teva, the Israeli pharma multinational, over Israel’s war on Gaza where more than 64,000 people have been killed.
The company terminated its Dublin lease in December as it shifts its focus away from the European market. It has been gradually winding down the Irish base.
A retirement fund in Detroit has filed a legal action against the Irish company, which counts major pharma firms among its clients.
The Aer Lingus owner said a “significant portion” of its pharma freight business comes from Ireland. The pharma sector here is in the sights of the US president.
The US president is playing a different game where the normal rules of engagement do not apply.
A patent dispute between Teva Pharmaceuticals and Bristol Myers Squibb, over a blood thinning drug, is playing out in the Irish courts.
The pharma firm is building a drug manufacturing site in Dublin, due for completion next year, and has been piling several tranches of capital into a new subsidiary to manage it.
© 2026 Currency Media Limited
